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Background:  The  elderly  are  more  often  referred  to  nephrologists  and  questions  about
indications for renal biopsy are increasing. The vascular lesions that appear with aging make
the  diagnosis  of  additional  nephropathy  more  difficult.  The  purpose  of  our  study  is  to
investigate  the  characteristics  of  renal  biopsies  in  the  elderly  in  order  to  evaluate  the
indications and their use in guiding specific therapeutic interventions.
Methods: Patients over 70 years who underwent a renal biopsy between 2000 and 2007 in
Rennes University Hospital were retrospectively analysed for biopsy complications, clinical
features, diagnosis, therapy and its complications, evolution and mortality.
Results: Among the 150 renal-biopsied patients, 60% had a glomerulopathy and 30% had
nephrotic  syndrome.  Biopsy  complications  occurred  in  3.3%.  64%  of  nephrotic  patients
received  immunosuppressive  treatment  and  62%  of  them  developed  drug-associated
complications. In the treated group, there was more remission and survival at day 1000 was
improved. 
Conclusions:  Renal  biopsy  may  be  indicated  in  the  elderly,  because  it  often  gives  a
therapeutically  useful  diagnosis  and  complications  are  rare  if  contra-indications  are
respected. Kidney biopsy revealed histological diagnoses that were not usually suspected by
the clinical presentation. In addition, immunosuppressive therapy did not alter the mortality
rate, but did increase survival at 3 years.  
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1. Introduction
Since vascular lesions often develop in the kidney with age, and complicate the often
present glomerulosclerosis of aging 1, the clinical diagnosis of glomerulopathy might be more
difficult  in  the  elderly  and  require  histological  assessment  of  renal  structure.  In  this
retrospective  study,  we  investigated  specific  characteristics  of  aging  patients  undergoing
renal  biopsy,  particularly  those  with  the  nephrotic  syndrome,  in  order  to  evaluate  the
indications  for  renal  biopsy  and  evaluate  current  treatments  in  the  population  of  elderly
patients.
The indications for renal biopsy in the elderly are increasing. In Japan, a recent study
showed that 15.1% of patients undergoing a renal biopsy in 2005 were more than 65 year old,
compared to 8.2% in 1995 2. In Italy, one centre reported that 38% of the biopsied patients
are now more than 65 year old 3 and in United Kingdom, 12% of kidney biopsies were done
in patients over the age of 60 in 1978 to 30% in 1990 1. In western France, a unique study
reported that mean age for renal biopsy in 1976 was 35 years and 52 years in 2000 4. These
modifications  could  be  explained  in  part  by  the  increase  in  longevity,  but  also  by  the
improvements of physiological health status in aging. Thus, the indications to kidney biopsy
and/or specific treatments in elderly may need to be re-evaluated.
Why  might  renal  biopsy  be  informative  in  aging  patients?  First,  the  clinical
presentation is often confusing in the elderly because of multiple associated conditions. For
instance, the clinical presentation  of acute renal disease, requiring specific treatment, may be
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unusual  superimposed on a  chronic  vascular  or  diabetic  nephropathy  5.  Secondly,  kidney
biopsy  may  be  more  risky  than  at  a  younger  age,  due  to  cortical  atrophy,  and  the  co
administration  of  anticoagulant  or  anti-platelet  therapy  due  to  cardiovascular  disease.
However, a few studies have shown that the incidence of complications in the elderly is not
greater than that in younger patients6-8. Finally, specific treatment for glomerulopathy is often
based on corticotherapy and/or immunosuppressive drugs which have serious side effects.
Thus,  giving  them  to  an  elderly  patient  without  a  biopsy-proven  diagnosis  may  not  be
acceptable. On the other hand, not giving the appropriate therapy to “physiologically-young
elderly” who would benefit would also be unacceptable 2, 6, 9-11 .
In  any  event,  consideration  for  performing  a  kidney  biopsy  must  include  careful
checking for contra-indications: small kidneys, anticoagulant or antiplatelet therapy, bleeding
disorders, uncontrolled hypertension or inability to remain recumbent for a few hours.
The objective of this study was to determine if our kidney biopsy policy in nephrotic
elderly patients led to a diagnosis without an unacceptable complication rate.  And that this
diagnosis led to a specific treatments permitting improvements in renal function and patient
survival.  Our policy for renal biopsies in aged patients includes the following indications:
proteinuria  with  extra-renal  signs  suggestive  of  systemic  disease;  nephrotic  syndrome  in
absence of long history of diabetes or established amyloidosis; acute renal failure without
evident explanation or rapid regression, unexplained chronic renal failure.  However, to our
mind,  renal  biopsy  is  not  indicated  in  elderly  patients  with  well-  documented,  slowly
progressive renal insufficiency.
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For this purpose, we retrospectively analyzed all the kidney biopsies done in patients
over the age of 70 years, with a focus on treatment and prognosis of those presenting with
nephrotic syndrome.  We chose this focus since most of the articles in the literature examined
the indications and results of renal biopsy 2, 3, 9, 12-14 15, but very few examined the follow-up
after specific treatments.
5
2. Materials and methods
2.1 Methods
Using  the  logiciel  Cristal-Report©  from the  pathology  department,  the  list  of  all
patients,  aged over  70 years,  who had undergone one or  more  renal  biopsy between  the
01/01/2000 and the 12/31/2007 was established. Renal transplant and biopsies for neoplasia
were excluded. 
The logiciel  “portfolio” from Pontchaillou  hospital  has  been  reviewed  for  clinical
data: age, indication and date of renal biopsy, presence or absence of  nephrotic syndrome
and final diagnosis.  The entire file of all the nephrotic patients was searched for: 
- sex, age, weight
- treatment and previous diseases
- number of renal biopsies, complications of renal biopsies
- proteinuria  (g/24h), total  serum protein (g/l),  albumin (g/l),  creatinine µmol/L, and
renal function (calculated by the simplified MDRD formula (Modification of Diet in
Renal Disease 16) at the time of renal biopsy
- hematuria, presence of edema, hypertension
- hypercholesterolemia (yes or no)
- treatment:  immunosuppressive  treatment,  treatment  by  ACEi  (Angiotensin
Converting  Enzyme  inhibitor)  or  ARB  (Angiotensin  II  Receptor  Blocker),
anticoagulation or antiplatelet therapy, other treatments
- remission or persistence of nephrotic syndrome
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- treatment complications 
- thrombotic complications
- evolution of renal function
- date of death.
Kidney  biopsies  were  done  by  an  urologist  or  a  nephrologist  under  ultrasound
guidance. 
2.2 Pathology studies
All  renal  biopsies  were  processed  for  light  microscopy,  and  immunofluorescence
according to standard techniques. No electron microscopy was performed. For each case, 8
glass slides with hematoxylin-eosin-safran (HES), periodic aid-Schiff (PAS), trichrome, and
Marinozzi  methenamine  silver  were  performed.  Immunofluorescence  was  done  on  3-µm
frozen  sections  by  use  of  a  panel  of  FITC-conjugated  rabbit  anti-human  antibodies  to
Fibrinogen, C3, C1q, IgG, IgM, IgA, Kappa, and Lambda light chains (Dako, Corporation).
Immunofluorescence staining was graded on a scale of 0 to 3+.
2.1 Statistics
Statistical analysis utilized the logiciel Excel® and XLSTAT®. Fischer exact test or
Mann Whitney test have been done according to the small number of patient for nominative
variables. The t-Test has been used for quantitative variables. Patient survival was calculated
by Kaplan Meier analysis using XLSTAT®.  
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3. Results
From the 1st of January 2000 to the 31st of December 2007, 157 patients, aged more
than 70 years underwent renal biopsy; 6 were excluded because the biopsy was done on a
transplanted kidney and one because it was done on a tumor, leaving a total of 150 patients.
3.1 Characteristics of the population
The mean number of kidneys biopsied was 18.7+/-5.4 biopsies/year. This number was
quite stable with time between 2000 and 2007. Seventy eight (52%) of the patients were men
and 72 (48%) were women; the mean age was 76.9 +/- 5.2 years,  the range was 70 to 95
years. Kidney biopsy indications included: 
- unexplained acute renal failure: 31%
- nephrotic syndrome: 30%
- rapidly progressive glomerulonephritis: 15%
- unexplained chronic renal failure: 11%
- chronic renal failure with proteinuria and/or hematuria:8%
- proteinuria and/or hematuria with normal renal function: 5%. 
3.2 Histological diagnosis
Ninety  one  (61%)  out  of  the  150  patients  had  a  glomerulopathy,  35  (23%)  a
tubulointerstitial nephropathy, 18 (12%) a vascular nephropathy and for 7 (4.6%) patients no
diagnosis  could be made (Table 1). Pauci-immune crescentic  glomerulonephritis (PICGN)
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with rapidly progressive  renal  failure  (with or  without  nephritic  syndrome) was the most
common  glomerulopathy  (37%).  Most  patients  with  vascular  nephropathy  had  benign
nephroangiosclerosis. Finally, the leading cause of tubulointerstitial nephropathy was drug
toxicity, especially after fluindione treatment (4 /13 cases).
3.3 Renal biopsy complications
Kidney biopsy was done under radiological control. Only 5 (3.3%) patients presented
benign  biopsy  complications;  two  patients  developed  a  hematoma  which  did  not  require
blood  transfusion,  three  developed  a  hematoma  requiring  blood transfusion  and  one  had
macroscopic hematuria requiring vesical lavages.
3.4 Patients with nephrotic syndrome
3.4.1 Characteristics
Forty  five  (30%)  of  the  150 elderly  patients  had  nephrotic  syndrome,  defined  as
proteinuria more than 3g/day and serum albumin less than 30 g/L. In this group, 33% were
men and 67% were women; their mean age was 77.9+/-6.13 years. Clinical characteristics
are  found  in  table  2.  Patients  with  MCD  (Minimal  Change  Disease)  or  FSGS  (Focal
Segmental Glomerulosclerosis) had significantly higher proteinuria than patients with MPGN
(Membrano-Proliferative  Glomerulonephritis)  or  MN  (Membranous  Nephropathy)
(9.11g/day vs 4.61 g/day, p=0.003). Mean serum creatinine was 199 +/-166µmol/L (from 53
to 831 µmol/L) the day of biopsy; GFR estimated by MDRD was more than 60 ml/min for 14
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(31%) patients, between 30 and 60 ml/min for 13 (29%) patients, between 15 and 30 ml/min
for 10 (22%) patients and less than 15 ml/min for 8 (18%) patients. 
3.4.2 Renal histology
The histological diagnosis of nephrotic patients (figure 1) revealed that, surprisingly,
the 2 leading diagnoses were MPGN (9 patients, 20%), and MCD (9 patients, 20%) (Table 2).
 All of the MPGN were type 1, all had microscopic hematuria and almost all (8 out of
9) had moderate to severe renal insufficiency. Non Hodgkin’s lymphoma was the cause of the
nephropathy in 3 patients, and biological cryoglobulinemia not associated with hepatitis C
virus  was  found  in  6  biopsies.  The  patients  with  MPGN  did  not  have  any  underlying
infectious  etiology.  Many  patients  with  Monoclonal  Gammapathy  of  Undeterminated
Siginificance (MGUS) were identified.
All  the  MCD were  primary  and  no  associated  neoplasia  was  detected  during  the
current  hospitalization or  follow-up. Surprisingly,  6 out  of 9 (66%) of those patients  had
microscopic hematuria at the time of the biopsy. In addition, 7 out of these 9 patients had
both glomerular changes and significant tubulointerstitial lesions. 
All the MN were idiopathic.
All 6 patients with amyloidosis had AL amyloidosis: 4 were associated with MGUS,
1  was  secondary  to  a  myeloma and  one  patient  had  Waldenstrom’s disease.  The  kidney
biopsy was done to investigate  nephrotic syndrome in all of those patients and the diagnosis
of amyloidosis was made with the help of the biopsy.
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3.4.3 Nephrotic syndrome complications
Almost  all  patients  (82%)  had  edema  at  the  time  of  diagnosis  and  61%  had
dyslipidemia. However,  only 3 (6.7%) developed venous thrombosis during the follow up.
All  of  them had  MN,  with  serum albumin  levels  above  20g/L.  On the  contrary,  several
patients without MN and with serum albumin levels below 20 g/L did not have preventive
anticoagulation and did not develop venous thrombosis.
3.4.4 Treatment and complications
Twenty-nine  nephrotic  patients  were  treated,  there  were  no  difference  for  sex
(p=0.74), and the median age was (77.5 vs 78.5 years) between the treated and non-treated
group.  There  was  no  major  difference  in  terms  of  nephropathy  between  both  groups:  6
MPGN  in  the  treated  group  vs  9  in  the  non  treated  ,  MCD(8  vs  9),  FSGS  (3  vs  4)  ,
amyloidosis (4 vs 6) and RPGN  (4 vs 4) except for MN (1 vs 7).
Almost half of the patients (47%) received ACEi or ARB during follow-up to treat
hypertension  and/or  proteinuria.  As  for  specific  glomerulonephritis  treatments,  25  (86%)
nephrotic patients received steroids and 64% received  various immunosuppressive regimens
(cyclophosphamide,  cyclosporine,  melphalan, gammaglobulins or rituximab) in addition to
steroids (table 3).  Eighteen (62%) treated patients developed therapeutic complications: 17
infections  (9 bacterial,  7  viral,  and one  pneumocystosis),  8  psychiatric  disorders,  5  bone
disorders, 4 diabetes and 3 adrenal insufficiency after stopping the steroids. One death was
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directly  linked  to  treatment  due  to  a  septic  shock  during  the  period  of  bone  marrow
suppression.
3.4.5 Renal and overall Survival
Of the 29 patients treated with steroids and/or immunosuppressive drugs, 16 (55%)
achieved complete remission, and 10 (34%) did not and 3 relapsed after stopping the therapy.
Out of the 16 untreated patients, 4 (25%) presented with spontaneous remission, and 1 (6%)
relapsed after initial spontaneous remission. In total, there was a significantly larger number
of remissions after treatment (p=0.0345).
Renal function remained stable in 36% patients, improved in 31% and decreased in
33%, all of whom presented with severe renal failure at the time of biopsy.
At  day  1000,  survival  was  significantly  better  in  the  treated  group  than  in  the
untreated group (p=0.0227) (figure 1). The most important factor influencing survival was
initial renal function (p=0.0042). Interestingly, neither persistence of nephrotic syndrome nor
treatment complications influenced overall survival. In addition, the mortality rate was higher
in the amyloidosis group (83%) than in the MCD group (11%).
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4. Discussion
This retrospective study revealed that performing renal biopsies in selected elderly
patients  is  safe  and  useful  in  establishing  a  precise  diagnosis  for  elaborating  appropriate
treatment strategies.
The  first  interesting  conclusion  drawn  from  this  study,  was  the  unusual  clinical
presentation of many patients, as had previously been described 9, 17, 18. Many of them, except
patients  with  amyloidosis,  had high blood pressure  and/or  hematuria  and/or  renal  failure,
even with  MCD nephropathy.  MCD is  thought  to  present  as  a  pure  nephrotic  syndrome,
defined by the absence of hematuria, renal failure or hypertension. Preexisting hypertension
or even glomerulosclerosis can confuse the clinical presentation 19. On the other hand, 25% of
MN patients  did not have  hematuria,  which is  a  classical  clinical  symptom of MN. This
statement confirms the importance of renal biopsy in the elderly for establishing a specific
diagnosis and in helping direct subsequent treatment. 
The  second  interesting  finding  is  the  presentation  of  those  patients  and  their
nephropathies. Some patients were more than 80, even 90 years old. The gender ratio was
33% men and 67% women, which is expected for those ages. The indication for renal biopsy
resembled previous published cohorts: ~30% presented with nephrotic syndrome and 30%
with  acute  renal  failure  1,  2,  9,  12,  14,  17,  20.  However,  the  histological  diagnoses  were  more
variable.  Renal  drug  toxicity  is  often  thought  to  be  a  frequent  cause  of  renal  failure,
especially in elderly patients, but represented only few cases in our population. We were not
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able to determine if it was a rare event or if it was not an indication for renal biopsy.  As
RPGN is the leading cause of renal biopsy in the elderly, it was much more frequent in this
elderly population than in younger patients 9. Contrary to the literature21, secondary MCD and
MN were  rare  compared  to idiopathic  MCD and MN even if  underlying  etiologies were
rigorously and systematically investigated.  The elevated rate of MPGN in our cohort was
surprising, and contrasted with the small number reported in the literature  1, 9. Furthermore,
the  MPGN  patients  did  not  have  an  underlying  infectious  etiology.  Many  patients  with
monoclonal  gammapathies  were  identified,  suggesting  that  MPGN  due  to  hematologic
disorders may be more frequent at least in Europe, than those due to infectious diseases. 
4.3 Biopsy or not biopsy?
This study also revealed that, if contraindications are respected and indications well
controlled,  kidney  biopsy  is  a  simple  and  worthwhile  tool,  almost  always  providing  a
diagnosis, and  is associated with few complications 9. A diagnosis could not be histologically
established in only 4.7%, and only 3.3% of the patients presented with complications most of
which were minimal. It does not look that different from the general population, since life-
threatening complications occur in less than 0.1% of biopsies and  bleeding occurs in up to
13%, 6 to 7% needing for therapeutic interventions 22.
Finally, our study suggests that aggressive therapy, even immunosuppressive therapy
can  be  performed  in  old,  and  even  very  old  patients,  without  an  unacceptable  rate  of
complications, especially infectious complications.
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We understand that our study has several  limits. It is a retrospective observational
study but there is no large prospective nor  retrospective  geriatric  cohort  in the literature.
Even the comparison between the treated and untreated groups should be carefully evaluated.
First of all, the patients were carefully selected prior to biopsy, and secondly, nephrologists
do not see all the elderly patients with renal disorders, even nephrotic syndrome. General
practitioners  may  have  selected  the  patients  and  referred  only  those  aged  patients  with
relatively  good  general  status  to  the  specialist.  In  addition,  nephrologists  only  perform
biopsies in aged patients who can bear the biopsy and a potential treatment. Most believe it is
unnecessary to take  the risk of biopsying a frail  patient  who cannot  undergo post-biopsy
treatment.  The  only  conclusion  to  be  made  from  the  survival  data  is  that  treatment  for
nephropathy,  even  including  steroids  or  other  immunosuppressive  therapy,  was  not
deleterious for this group of selected elderly patients.
5. Conclusion
In conclusion, this study, like the recent published data of Moutzouris 15 showed that
renal biopsy is feasible and may be indicated in elderly patients, as long as contra-indications
are respected. Histological diagnosis is necessary to clarify a clinical situation, confused by
previous  co-morbidities  and  may  help  clinicians  to  choose  the  appropriate  therapeutic
intervention. Glomerulonephritis in the elderly is not uncommon, often difficult to diagnose
without histology, and often requires specific and sometimes aggressive therapies. 
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Figure legends
Table 1: Histological diagnosis for all the biopsied-patients over 70 years.
61% out of the 150 patients had a glomerulopathy, 23% a tubulointerstitial nephropathy, 12% a vascular
nephropathy and for 4.6% patients no diagnosis could be made on the biopsy
Anti-GBM: anti glomerular membrane basement disease
FSGS: Focal segmental glomerulosclerosis
MCD: Minimal change disease
MN: Membranous nephropathy
MPGN: Membranoproliferative glomerulonephritis
ATN: Acute tubular necrosis
TMA: Thrombotic microangiopathie
Table 2: clinical characteristics of nephrotic patients 
Patients with MCD, FSGS had significantly higher proteinuria than patients with MPGN or MN
(p=0.003).
GFR : Glomerular filtration rate
MCD: Minimal change disease
FSGS: Focal segmental glomerulosclerosis
MN : Membranous nephropathy
MPGN: Membranoproliferative glomerulonephritis
PICGN: Pauci-immune crescentic glomerulonephritis
Table 3: number of treated patients and complications of treatment, according to the initial histological
diagnosis. No difference has been seen between groups.
MCD: Minimal change disease
FSGS: Focal segmental glomerulosclerosis
MN : Membranous nephropathy
MPGN: Membranoproliferative glomerulonephritis
PICGN: Pauci-immune crescentic glomerulonephritis
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